NKE Research Update — June 20, 2026
Updated Thesis
NIKE, Inc. is the leading global athletic footwear and apparel brand with a strong competitive moat driven by its iconic brand and extensive innovation capabilities. The company is currently facing earnings pressure with a 34.5% decline in earnings in the most recent quarter and a 10% revenue decline in fiscal 2025, reflecting challenges from tariff-related cost pressures, intense competition, and a shift from direct-to-consumer growth to a more mature wholesale-driven model.
The investment grade as of this refresh is B — solid business quality. B-tier business, C-tier valuation
Key Metrics at a Glance
- Revenue growth: +0.1% year over year
- Net margin: 4.8%
- Forward P/E: 29.7x
- Fair value upside: +38.7% to our estimate of $63
Current price: $45.20
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. NIKE, Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full NKE research →](/stocks/NKE)